Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Be...
Main Authors: | Francesca Colapietro, Giovanni Angelotti, Chiara Masetti, Dana Shiffer, Nicola Pugliese, Stella De Nicola, Francesco Carella, Antonio Desai, Monica Ormas, Marta Calatroni, Paolo Omodei, Michele Ciccarelli, Stefano Aliberti, Francesco Reggiani, Michele Bartoletti, Maurizio Cecconi, Ana Lleo, Alessio Aghemo, Antonio Voza |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/15/8/1738 |
Similar Items
-
Ursodeoxycholic acid and cancer prevention
by: A. R. Reyzis
Published: (2019-10-01) -
Experience of using ursodeoxycholic acid to dissolve gallstones
by: V. V. Tsukanov, et al.
Published: (2020-01-01) -
Ursodeoxycholic Acid Halts Pathological Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy
by: Menaka C. Thounaojam, et al.
Published: (2020-06-01) -
Polynosological effects of ursodeoxycholic acid (UDCA). Practice of using
by: V. M. Makhov, et al.
Published: (2016-12-01) -
Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid
by: Jessica T. Hochberg, et al.
Published: (2023-06-01)